Astellas calls time on ex-Dynogen US facility as it tidies R&D network

Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.

Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.

The centre in Durham, North Carolina was originally acquired from Dynogen Pharmaceuticals in 2006, and has since been conducting drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapeutic Category

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.